Danne, Thomas, 1959-
Danne, Thomas
Danne, T.
Danne, T. (Thomas), 1959-
Thomas Danne German paediatrician
Danne, T. (Thomas)
VIAF ID: 45477700 ( Personal )
Permalink: http://viaf.org/viaf/45477700
Preferred Forms
- 200 _ | ‡a Danne ‡b Thomas
- 100 1 _ ‡a Danne, T.
-
- 100 1 _ ‡a Danne, T. ‡q (Thomas)
- 100 1 _ ‡a Danne, T. ‡q (Thomas), ‡d 1959-
-
- 100 1 _ ‡a Danne, Thomas
- 100 1 _ ‡a Danne, Thomas ‡d 1959-
- 100 1 _ ‡a Danne, Thomas, ‡d 1959-
-
- 100 0 _ ‡a Thomas Danne ‡c German paediatrician
4xx's: Alternate Name Forms (8)
5xx's: Related Names (3)
- 551 _ _ ‡a Berlin ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 551 _ _ ‡a Hannover ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Medizinische Hochschule Hannover ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes : the DAPADream study | |
Adipositas, Diabetes, und Fettstoffwechselstörungen im Kindesalter | |
An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria | |
The automated pancreas : the review of technologies and clinical practice | |
CGM interpretieren Grundlagen, Technologie, Charakteristik und Konsequenzen des kontinuierlichen Glukosemonitorings (CGM) | |
Clinical targets for continuous glucose monitoring data interpretation : recommendations from the international consensus on time in range | |
Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity : a randomised controlled crossover trial | |
Diabetes bei Kindern und Jugendlichen Grundlagen - Klinik - Therapie | |
Diabetesberatung zum Hybrid-AID-System bei Typ-1-Diabetes: neue Perspektiven und Therapieempfehlungen = Diabetes Education on Hybrid-AID-System in Type 1 Diabetes: new perspectives and recommendations | |
The digital/virtual diabetes clinic : the future is now - recommendations from an International Panel on Diabetes Digital Technologies Introduction | |
DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany | |
Familiäre Hypercholesterinämie ein Ratgeber für Eltern und Kinder : Fr1dolin Früherkennung von Typ 1 Diabetes und Hypercholesterinämie in Niedersachsen | |
Faster compared with standard insulin aspart during day-and- night fully closed-loop insulin therapy in type 1 diabetes : a double-blind randomized crossover trial | |
Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis | |
InRange Comparison of the second-generation basal insulin analogues Glargine 300 U/mL and Degludec 100 U/mL in persons with type 1 diabetes using continuous glucose monitoring | |
Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes | |
Insulin treatment in children and adolescents with diabetes | |
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes | |
International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors | |
Lived experience of advanced hybrid closed-loop versus hybrid closed-loop : patient-reported outcomes and perspectives | |
a new paradigm in treatment of type 2 diabetes | |
Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis | |
Ninety day memory read-out from 370 international pediatric patients demonstrates the safety and felxibility of continuous subcutaneous insulin infusion (CSII) in all age groups | |
Pädiatrische Endokrinologie und Diabetologie | |
Patient and disease characteristics of adult patients with type 1 diabetes in Germany: an analysis of the DPV and DIVE databases | |
Pediatric diabetes training for healthcare professionals in Europe : time for change | |
The PedPump survey : more than seven daily boluses and less basal insulin are associated with lower GlyHbA1c in 1086 chuildren with T1 DM from 17 countries | |
Quality control of diabetes care and chronic complications in young people after St. Vincent and Kos 19 tables | |
Real-world‐data of 12‐month adjunct SGLT2‐inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: improved HbA1c without DKA | |
Risk of celiac disease in children with type 1 diabetes is modified by positivity for HLA-DQB1*02-DQA1*05 and TNF -308A | |
Structural and functional abnormalities in subclinical diabetic angiopathy | |
The SWEET project 10-year benchmarking in 19 countries worldwide is associated with improved HbA1c and Increased use of diabetes technology in youth with type 1 diabetes | |
Universal screening for familial hypercholesterolemia in two populations | |
Use of continuous glucose monitoring in children and adolescents | |
Use of insulin pump therapy in the pediatric age-group : consensus statement from the European Society for paediatric endocrinology, the Lawson Wilkins pediatric endocrine society, and the International society for pediatric and adolescent diabetes, endorsed by the American diabetes association and the European association for the Study of diabetes | |
Vergleich einer Erstbehandlung des Diabetes mellitus im Kindesalter mit Humaninsulin gegenüber hochgereinigtem Schweineinsulin | |
A worldwide perspective on COVID-19 and diabetes management in 22,820 children from the SWEET project : diabetic ketoacidosis rates increase and glycemic control is maintained |